LEADER 01180nam--2200397---450 001 990002733130203316 005 20220601121040.0 010 $a2-8040-0358-2 035 $a000273313 035 $aUSA01000273313 035 $a(ALEPH)000273313USA01 035 $a000273313 100 $a20060411d1988----km-y0itay0103----ba 101 $afre 102 $aBE 105 $aa|||||||001yy 200 1 $a<> joker$eroman$fJean Muno$gpréface de Michel Lambert$glecture de Daniel Laroche 210 $aBruxelles$cLabor$dcopyr. 1988 215 $a188 p., [4] c. di tav.$cill.$d18 cm 225 2 $aEspace Nord$v47 410 0$12001$aEspace Nord$v47 676 $a843.914 700 1$aMUNO,$bJean$0245158 702 1$aLAMBERT,$bMichel 702 1$aLAROCHE,$bDaniel 801 0$aIT$bsalbc$gISBD 912 $a990002733130203316 951 $aXV.4. Coll. 1/152$b183679 L.M.$cXV.4. Coll. 959 $aBK 969 $aFF 979 $aMARIASEN$b90$c20060411$lUSA01$h1039 979 $aMARIASEN$b90$c20060411$lUSA01$h1045 979 $aMARIASEN$b90$c20060411$lUSA01$h1306 979 $aMARIASEN$b90$c20060411$lUSA01$h1307 996 $aJoker$9214203 997 $aUNISA LEADER 01318nam 2200337z- 450 001 9910694419603321 005 20080611090213.0 035 $a(CKB)5860000000018176 035 $a(BIP)022723652 035 $a(EXLCZ)995860000000018176 100 $a20220406c2008uuuu -u- - 101 0 $aeng 200 10$aAssessing the impact of a safe and equitable biosimilar policy in the United States $ehearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Tenth Congress, first session, May 2, 2007 215 $a1 online resource (vi, 184 p.) $cill 311 $a0-16-080887-1 517 $aAssessing the Impact of a Safe and Equitable Biosimilar Policy in the United States 606 $aBiologicals$zUnited States 606 $aPharmaceutical biotechnology$zUnited States 606 $aGeneric drugs$zUnited States 610 $aBiologicals 610 $aPharmaceutical biotechnology 610 $aGeneric drugs 610 $aMedical 610 $aTechnology & engineering 615 0$aBiologicals 615 0$aPharmaceutical biotechnology 615 0$aGeneric drugs 906 $aBOOK 912 $a9910694419603321 996 $aAssessing the impact of a safe and equitable biosimilar policy in the United States$93190062 997 $aUNINA